Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perspectives on complement in xenotransplantation.

Tom E Mollnes1, Arnt E Fiane

  • 1Institute of Immunology, Rikshospitalet University Hospital, N-0027 Oslo, Norway. t.e.mollnes@labmed.uio.no

Molecular Immunology
|August 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complement activation in patients with post-acute sequelae after SARS-CoV-2 infection.

Frontiers in immunology·2026
Same author

Implantation of a Continuous-Flow Left Ventricular Assist Device During Cardiopulmonary Bypass Is Associated with a Significant and Transient Acute Thromboinflammatory Response.

International journal of molecular sciences·2026
Same author

Distinct Proteomic and Transcriptomic Profiles in T-cells and Monocytes in Patients with Common Variable Immunodeficiency: an Exploratory Study.

Journal of clinical immunology·2026
Same author

Validation of shear wave elastography for assessing myocardial fibrosis in patients with end-stage heart failure.

European heart journal. Cardiovascular Imaging·2026
Same author

Extracellular mitochondrial DNA activates complement and is associated with complement activation in patients with out-of-hospital cardiac arrest.

Scientific reports·2025
Same author

Heart transplantation in Norway 1983–2023.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2025
Same journal

m6A modification of LINC00458 enhances HMOX1 stability via ELAVL1 recruitment to promote ferroptosis and aggravate asthma.

Molecular immunology·2026
Same journal

Overexpression of Hes1 inhibits cigarette smoke-induced mitochondrial apoptosis in AT2 cells by activating the Pgc-1α/Tfam signaling pathway.

Molecular immunology·2026
Same journal

Progesterone promotes favorable pregnancy outcomes in recurrent spontaneous, abortion by attenuating NK Cell overactivation and upregulating the cAMP/PKA/CREB signaling axis.

Molecular immunology·2026
Same journal

Oleanolic acid alleviates hepatic fibrosis by inhibiting liver macrophage recruitment and polarization.

Molecular immunology·2026
Same journal

Cordycepin attenuates diabetic nephropathy by dual-pathway activation of TFEB to restore autophagy and ameliorate podocyte injury.

Molecular immunology·2026
Same journal

Endothelial-derived TWEAK drives granulosa cell apoptosis in PCOS via the Fn14-oxidative stress axis.

Molecular immunology·2026
See all related articles

Complement and anti-Gal antibodies drive hyperacute rejection in xenotransplantation. Strategies to control complement activation, including soluble inhibitors, are crucial for improving long-term graft survival and overcoming rejection barriers.

Area of Science:

  • Immunology
  • Transplantation Biology
  • Biomedical Engineering

Background:

  • Hyperacute rejection of xenografts, particularly pig organs to humans, is primarily mediated by complement and anti-Gal antibodies.
  • While transgenic pigs expressing human complement regulatory proteins can evade hyperacute rejection, subsequent acute and delayed rejections remain concerns.
  • Complement activation also exacerbates ischemia-reperfusion injury (IRI), impacting overall graft health regardless of the donor source.

Purpose of the Study:

  • To review the multifaceted role of complement in xenograft rejection beyond hyperacute rejection.
  • To explore therapeutic strategies targeting complement activation for improved xenotransplantation outcomes.
  • To highlight the ongoing need for further research into complement inhibition in xenotransplantation.

Related Experiment Videos

Main Methods:

  • Review of existing literature on complement's role in xenotransplantation.
  • Analysis of data regarding transgenic pig models and complement regulatory proteins.
  • Discussion of therapeutic interventions targeting fluid-phase complement activation.

Main Results:

  • Complement plays a significant role not only in hyperacute rejection but also in acute vascular and delayed xenograft rejections.
  • Early complement-mediated endothelial cell activation, even if not causing hyperacute rejection, can impair long-term graft function.
  • Soluble complement inhibitors show promise as an adjuvant therapy during organ harvesting and the early post-transplant period.

Conclusions:

  • Effective control of complement activation is essential for successful xenotransplantation, extending beyond preventing hyperacute rejection.
  • Pharmacological manipulation of complement, particularly fluid-phase inhibition, warrants further development and clinical investigation.
  • While advancements in xenotransplantation are promising, a comprehensive understanding and management strategy for complement-mediated injury are still required.